Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diagnos Laboratorium Utama Tbk. (DGNS) vs Trimegah Bangun Persada Tbk. (NCKL) Price & Performance

Diagnos Laboratorium Utama Tbk.Trade
Trimegah Bangun Persada Tbk.Trade

Price performance (Past 24H)

Key statistics

Diagnos Laboratorium Utama Tbk. vs Trimegah Bangun Persada Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp228 (market cap 319B, 124.3K 24h volume), while Trimegah Bangun Persada Tbk. trades at Rp925 (market cap 57.42T, 37.91M 24h volume). The key difference: Trimegah Bangun Persada Tbk. is far larger — about 180× Diagnos Laboratorium Utama Tbk.'s market cap, and Trimegah Bangun Persada Tbk. is more actively traded (37.91M versus 124.3K). Which is the better fit depends on your goals.

DGNSNCKL
Market Cap
319B57.42T
Volume
124.3K37.91M
Lot
1.24K379.1K
Turnover
28.28M34.83B
Average Price
227.48918.76
Value
28.28M34.83B
Indicative Equilibrium Price
228925
Indicative Equilibrium Volume
10010.28K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DGNS
View details
NCKL
View details

About Diagnos Laboratorium Utama Tbk.

PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.

Read more on DGNS

About Trimegah Bangun Persada Tbk.

PT Trimegah Bangun Persada Tbk. (the Company) was established in Indonesia based on Notarial Deed of Erna Priyono, S.H., No. 03 dated September 6, 2004.

Read more on NCKL